Ridaforolimus (Deforolimus AP23573) BEZ235 SF1126 XL418 XL765 XL147 Everolimus (RAD001) PX-866 XL281 Perifosine XL228 RDEA119 GDC-0941 bismesylate PF-04691502 GDC-0973 Sirolimus (Rapamune) GDC-0980 Temsirolimus (Torisel, CCI-779) Selumetinib (AZD6244)

XL765

This drug, under preclinical development by Exelixis, inhibits both PI3K and mTOR.  It is expectd to enter a Phase I trial late in 2007.

For information at the site of the manufacturer click here.